Show simple item record

dc.contributor.authorTayyebikhosroshahi, H
dc.contributor.authorSanaat, Z
dc.contributor.authorFarhoudi, M
dc.contributor.authorKeyani, S
dc.contributor.authorKhoshjoo, F
dc.contributor.authorTayyebikhosroshahi, M
dc.date.accessioned2018-08-26T09:45:25Z
dc.date.available2018-08-26T09:45:25Z
dc.date.issued2011
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/58733
dc.description.abstractObjective: To determine the warfarin maintenance dose in Iranian patients.Methods: This multicenter study was conducted between January 2007 and January 2008 in 5 different large cities of Iran. Patients older than 12 years receiving warfarin were included. During the first days of warfarin use, international normalized ratio (INR) was measured daily and after that every 1-2 weeks, with a duration of at least one month. The warfarin dose was considered to be stabilized if the INR remained unchanged on 3 consecutive measurements at a level between 2-3. Then mean dose of the last 3 warfarin doses was calculated. Results: One hundred and fifty patients receiving warfarin took part in this study. No significant differences were noted in the mean warfarin dosage among the 5 cities, and between men and women (p=0.228). The warfarin daily dose and INR did not shown any statistical difference between men and women. The warfarin dose statistically decreased in patients older than 60 years old (p=0.004 versus 45-60 years, and p=0.002 versus 30-45 years). This study showed that the required mean warfarin dose in Iranian patients was approximately 4 mg to achieve an INR between 2-3. Conclusion: Considering geographic and ethnic differences of Iranian patients, attention to the dose determination of warfarin is of importance.
dc.language.isoEnglish
dc.relation.ispartofNeurosciences
dc.subjectwarfarin
dc.subjectadult
dc.subjectaged
dc.subjectarticle
dc.subjectcardiovascular disease
dc.subjectcross-sectional study
dc.subjectdeep vein thrombosis
dc.subjectethnic difference
dc.subjectfemale
dc.subjectheart atrium fibrillation
dc.subjecthuman
dc.subjectinternational normalized ratio
dc.subjectIran
dc.subjectlung embolism
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmulticenter study
dc.subjectocclusive cerebrovascular disease
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAnalysis of Variance
dc.subjectAnticoagulants
dc.subjectBody Mass Index
dc.subjectCross-Sectional Studies
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectIran
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectReference Values
dc.subjectRetrospective Studies
dc.subjectVascular Diseases
dc.subjectWarfarin
dc.subjectYoung Adult
dc.titleWarfarin maintenance dose in Iranian patients: A cross sectional study in 5 cities of Iran
dc.typeArticle
dc.citation.volume16
dc.citation.issue2
dc.citation.spage125
dc.citation.epage128
dc.citation.indexScopus


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record